Bocom Intl released a report on August 30, stating that Innovent Bio's mid-year performance exceeded expectations, with adjusted losses narrowing more than expected by the market. Product sales showed strong growth, and operational efficiency continued to improve. The bank has raised its revenue forecast for Innovent Bio from 2024 to 2026 by 2% to 8%, and the target price has been raised to HK$60. It believes that the company's extensive and differentiated product portfolio, along with its diversified product development plans, can consolidate its leading position in the industry.